First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

PURPOSE: CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expres...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S., Chesney, Jason, Orcutt, James, Spigel, David R., Reck, Martin, O’Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J., Szustakowski, Joseph D., Green, George, Chang, Han, Ramalingam, Suresh S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494267/
https://ncbi.nlm.nih.gov/pubmed/30785829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados